It is important to note that CD10, CD22 and CD23 have been reported as being expressed in 3%, 33% and 61% of patients.[6] The observation that these antigens were not expressed in the majority of RPCI-WM1 cells was not altogether unforeseen as this cell line was derived from a terminally advanced stage WM patient and suggests the shedding of “typical” surface antigens and upregulation of others (i.e. CD28) by the tumor clone, perhaps to retain its tumorigenicity. This evidence concerns the gene MME and neoplasm.